CORRELATES OF NON-FATAL OPIOID OVERDOSE AMONG A COHORT OF PEOPLE WHO INJECT DRUGS IN MELBOURNE, AUSTRALIA

PENELOPE HILL¹,², PAUL DIETZE¹,², MARK STOOVE¹,²

¹Behaviours and Health Risks Program, Burnet Institute, Melbourne, Australia, ²School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia

Introduction and Aims: Many people who inject drugs (PWID) are at risk of non-fatal opioid overdose but few contemporary Australian studies have analysed this risk. In this study we use data from SuperMIX, a cohort study of PWID, to identify the correlates of ever and recent opioid overdose of PWID in Melbourne.

Design and Methods: The prevalence of reports of lifetime overdose and recent (past six months) were calculated from SuperMIX data (N=757). Associations between these outcomes and sociodemographic characteristics, drug and injecting related behaviours and self-reported health service use were examined using logistic regression.

Results: 42% of the cohort reported ever having experienced an opioid overdose and 23% reported overdosing in the past six months. Reports of recent overdose were positively associated with emergency department (ED) access in the last month (AOR 2.62, 95% CI 1.45-4.71; p=0.001) and past-month benzodiazepine use (AOR 2.37, 95% CI 1.20-4.67; p=0.012). Participants who reported ever having overdosed were more likely to report having ever been incarcerated (AOR 1.41, 95% CI 1.03-1.92; p=0.031), having accessed an ED (AOR 1.41, 95% CI 1.03-1.92; p=0.031) or psychologist or psychiatrist in the last month (AOR 1.54, 95% CI 1.02-2.33; p=0.041), or used benzodiazepines in the last month (AOR 1.91, 95% CI 1.33-2.73; p<0.001).

Discussions and Conclusions: We identified a range of factors related to opioid overdose experience in the SuperMIX cohort at baseline. Further research is needed to understand how these patterns vary over time in the cohort.

Disclosure of Interest Statement: PD has received an investigator-driven grant from Gilead Sciences for unrelated work on hepatitis C and an untied educational grant from Reckitt Benckiser for unrelated work on the introduction of buprenorphine-naloxone into Australia.

Support: The MIX study was funded by The Colonial Foundation Trust and the Australian National Health and Medical Research Council (NHMRC Project Grant #545891). PD is supported by an NHMRC Senior Research Fellowship.